Vol. 2 No. 7 (2022)
Reimbursement Reviews

Nivolumab (Opdivo)

Published July 22, 2022

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses nivolumab (Opdivo) for injection, IV infusion, 10 mg nivolumab/mL, 40 mg and 100 mg single-use vials.
  • Indication: Opdivo in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of adult patients with human epidermal growth factor receptor 2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma.